Tezepelumab is an investigational human monoclonal antibody specific for the epithelial-cell–derived cytokine thymic stromal lymphopoietin. An editorial suggests that it appears to be the broadest and most promising biologic for the treatment of persistent uncontrolled asthma to date. It calls for future studies to confirm the efficacy and safety of this biologic.